HeartBeam Advances U.S. Commercial Launch, Raises $11.5M, Cuts Q1 Loss to $4.7M
BEAT•HeartBeam launched its initial commercial partnerships in major U.S. markets and advanced its FDA-cleared 3D ECG platform with progress on heart attack detection and ambulatory patch initiatives. The April public offering raised $11.5 million and Q1 net loss narrowed to $4.7 million from $5.5 million year-on-year.
1. Initial Commercial Partnerships and Technology Progress
HeartBeam launched initial commercial partnerships in key U.S. markets and began deploying its FDA-cleared 3D ECG platform for ambulatory cardiac monitoring. Progress continued on its heart attack detection algorithms and next-generation ECG patch initiatives to enhance its cardiac intelligence offerings.
2. First-Quarter 2026 Financial Performance
In Q1 2026, HeartBeam reported a net loss of $4.7 million, an improvement from $5.5 million in Q1 2025. Research and development expenses declined year-on-year, reflecting efficiencies as the company moves toward broader commercialization.
3. April Public Offering Proceeds
In April 2026, the company completed a public offering raising $11.5 million in gross proceeds. These funds are earmarked to support expanded commercial deployments and ongoing technology development across its cardiac monitoring platforms.
